BIIB/ELN/TEVA/NVS/MNTA—Robyn Karnauskas of Deutsche Bank forecasts that US Tysabri sales will fall from $633M in 2010 to $376M in 2015 as newer and safer MS drugs reach the market. Source: http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201008191623dowjonesdjonline000542&title=brain-infections-from-biogen-elan-ms-drug-continue-to-rise